Trial Profile
Safety and tolerability, efficacy of Teriflunomide in patients with relapsing-remitting multiple scelrosis: A real world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jan 2020
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis